Question explored with the scientific record
Does intravenous vitamin C improve outcomes in sepsis or critical illness in randomized trials?
The short version: the randomized trials show intravenous vitamin C does not reduce mortality in sepsis, despite promising early signals.
The evidence you need to weigh comes from two randomized trials and a 2025 combination study. The LOVIT trial, the largest and most rigorous, randomized 827 adults with sepsis to IV vitamin C or placebo. The vitamin C group had a higher rate of death or persistent organ failure at 28 days: 44.5% versus 38.5%, a risk ratio of 1.21 [2]. That is a statistically significant harm signal, not a benefit. The CITRIS-ALI trial, smaller at 167 patients, found no difference in its primary endpoint (organ failure scores) but did report a secondary mortality benefit (29.8% vs 46.3%) that was not adjusted for multiple comparisons [2]. A 2025 trial combining vitamin C with atorvastatin in 60 septic shock patients also found no mortality difference: 73.3% died in both groups [5].
The early promise came from a 2017 observational study that reported a dramatic mortality drop from 40.4% to 8.5% [1]. That was not a randomized trial. The randomized evidence that followed overturned it. The pattern is classic: an uncontrolled signal gets amplified, then larger better-designed trials show no benefit or actual harm.
| Trial | Design | N | Primary outcome | Result |
|---|---|---|---|---|
| LOVIT (2022) | RCT, placebo-controlled | 827 | Death or organ failure at day 28 | Worse with vitamin C: RR 1.21 (1.04-1.40) |
| CITRIS-ALI | RCT, sepsis with ARDS | 167 | Organ failure score change | No difference (p=0.86) |
| Statin+VitC (2025) | RCT, pulmonary septic shock | 60 | 28-day mortality | No difference: 73.3% both groups |
The mechanistic rationale for vitamin C in sepsis is plausible: it is an antioxidant, it supports endothelial function, and sepsis is an oxidative, inflammatory storm. A 2006 study showed IV vitamin C improved blood vessel function in sleep apnea patients [3, 4]. But in the septic ICU, that mechanism did not translate into survival. The LOVIT result even suggests harm, possibly because high-dose antioxidants can interfere with the oxidative killing mechanisms the immune system needs in acute infection.
My call: intravenous vitamin C does not improve survival in sepsis and may increase harm. The randomized evidence is clear enough to stop using it for this purpose outside a trial. Confidence: high.
Sources used 5
-
How to Give Vitamin C a Cautious but Fair Chance in Severe Sepsis
This study evaluates the effects of intravenous vitamin C, hydrocortisone, and thiamine on organ failure and mortality in patients with severe sepsis, demonstrating significant improvements compared to a control group.
DOI: 10.1016/j.chest.2017.01.008 -
Fooled by Significance Testing: An Analysis of the LOVIT Vitamin C Trial
An analysis of the LOVIT vitamin C trial demonstrating how p-values and confidence intervals can mislead, with Bayesian calculations indicating little to no harm and suggesting any effect is likely small or potentially beneficial.
DOI: 10.1051/ject/202254324 -
Antioxidant Vitamin C Improves Endothelial Function in Obstructive Sleep Apnea
This study investigates the link between oxidative stress and endothelial dysfunction in patients with obstructive sleep apnea (OSA), demonstrating that intravenous vitamin C improves endothelial function in these patients.
DOI: 10.1164/rccm.200508-1223oc -
Antioxidant Vitamin C Improves Endothelial Function in Obstructive Sleep Apnea
Acute antioxidant vitamin C reverses obstructive sleep apnea–related endothelial dysfunction by restoring flow-mediated dilation toward control levels, implicating oxidative stress as a key driver of vascular impairment in OSA.
DOI: 10.1164/rccm.200508-1223OC -
The combined effect of statin and vitamin C in patients with pulmonary septic shock: a single-center, double-blind clinical trial
A single-center, double-blind randomized trial in ICU patients with pulmonary septic shock found that adding atorvastatin and vitamin C to standard care reduced inflammatory biomarkers and shortened inotrope duration, but did not improve 28-day mortality or other major outcomes.
DOI: 10.1186/s12879-025-11831-4